You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

 

Online download statistics by month:

Online download statistics by month: November 2023 to August 2024

AbstractFullPdf
Nov 2023656062
Dec 2023183031
Jan 2024274026
Feb 2024124036
Mar 2024126030
Apr 2024130041
May 2024120026
Jun 2024182019
Jul 2024146024
Aug 2024164022
Total21050317